Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral semaglutide monotherapy delivers HbA1c improvements in type 2 diabetes

Key clinical point: Oral semaglutide monotherapy significantly reduced HbA1c in patients with type 2 diabetes, compared with placebo in patients managed by diet and exercise alone.

Major finding: At 26 weeks, the differences in HbA1c for medication daily doses of 3 mg, 7 mg, and 14 mg using an intention-to-treat analysis, were –0.6%, –0.9%, and –1.1%, respectively (P less than .001 for all).

Study details: A randomized, double-blind, placebo-controlled, multicenter trial of 703 adults with type 2 diabetes.

Disclosures: Novo Nordisk funded the study. The lead author disclosed relationships with Novo Nordisk, and several coauthors disclosed relationships with or employment by the company.

Citation:

Aroda VR et al. Diabetes Care. 2019 Jul. doi: 10.2337/dc19-0749.